Zosano Pharma (ZSAN) Earning Somewhat Favorable Press Coverage, Study Finds
Media stories about Zosano Pharma (NASDAQ:ZSAN) have trended somewhat positive recently, Accern Sentiment Analysis reports. Accern scores the sentiment of news coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Zosano Pharma earned a news impact score of 0.08 on Accern’s scale. Accern also gave media headlines about the biotechnology company an impact score of 44.9609458741641 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
Here are some of the news headlines that may have impacted Accern’s analysis:
- Mid-Day Innovative Stocks: Alliance One International, Inc. (NYSE:AOI), Zosano Pharma Corporation (NASDAQ:ZSAN) (thestreetpoint.com)
- BTIG Research Initiates Coverage on Zosano Pharma (ZSAN) (americanbankingnews.com)
- After-Hours Stock Movers 06/27: (EDGE) (ZSAN) (MSG) Higher; (PIR) (BBBY) (XON) Lower (more…) (streetinsider.com)
- Zosano Pharma (ZSAN) Stock Can Reach $19 in the Next 12 Months, Says BTIG (finance.yahoo.com)
Several equities analysts recently issued reports on the company. ValuEngine raised Zosano Pharma from a “strong sell” rating to a “sell” rating in a research note on Tuesday, April 3rd. BTIG Research assumed coverage on Zosano Pharma in a research note on Thursday, June 28th. They set a “buy” rating on the stock.
Zosano Pharma (NASDAQ:ZSAN) last posted its earnings results on Tuesday, May 15th. The biotechnology company reported ($4.16) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($4.60) by $0.44.
Zosano Pharma Company Profile
Zosano Pharma Corporation, a clinical stage biopharmaceutical company, focuses on providing therapeutics to patients suffering from migraine using its Adhesive Dermally-Applied Microarray technology. Its lead product candidate is M207, a proprietary formulation of zolmitriptan used for the treatment of migraine.
Receive News & Ratings for Zosano Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zosano Pharma and related companies with MarketBeat.com's FREE daily email newsletter.